The table below shows Kiniksa Pharmaceuticals, Ltd.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
$50.20M
$22.32M
$3.99M
-$4.27M
-$36.85M
-$40.12M
Capital expenditure
$161.00K
$99.00K
$84.00K
$24.00K
-
$54.00K
Investing cash flow
-$31.92M
-$51.54M
$25.52M
-$37.92M
-$22.72M
$44.83M
Dividends paid
-
-
-
-
KNSA operating cash flow (10-K history)
Kiniksa Pharmaceuticals, Ltd. reported operating cash flow of $137.99M for fiscal year 2025. That is up 437.1% from $25.69M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$50.22M (FY 2017) to $137.99M. Figures come from the company's audited annual reports as filed with the SEC.